Adma Biologics (ADMA) reported $510M in revenue for fiscal 2025, +19.6% year on year. That ranks #2194 by revenue among 2853 SEC filers and #213 in Healthcare. Net income was $147M, a net margin of 28.8%. Revenue has grown 59.2% a year on average since 2011 ($761,042 then). The fiscal 2025 balance sheet shows $624M in total assets, $87.6M in cash and $69.3M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $510M | +19.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $293M | +33.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $191M | +37.7% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $147M | −25.7% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $50.4M | −57.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $22.6M | +174.4% | FY20252025-12-31 |
| Total assetsAssets | $624M | +27.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $477M | +36.8% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $87.6M | −15.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $69.3M | −4.2% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $114M | $45.3M | Open → |
| Q2 20262026-06-30 | $124M | $37.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Adma Biologics, Inc.
- Ticker
- ADMA
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0001368514
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Mirum PharmaceuticalsMIRM | $521M | −$23.4M |
| VeracyteVCYT | $517M | $66.4M |
| InotivNOTVQ | $513M | −$68.6M |
| Adma BiologicsADMA | $510M | $147M |
| GlaukosGKOS | $507M | −$188M |
| Starling OncologySTLN | $503M | $60.6M |
| Bridgebio PharmaBBIO | $502M | −$733M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Adma Biologics — Key figures |url=https://companiesranked.com/en/company/adma-biologics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Adma Biologics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/adma-biologicsBibTeX
@misc{companiesranked-en-company-adma-biologics-2026,
author = {{CompaniesRanked}},
title = {{Adma Biologics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/adma-biologics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001140361-26-006815 · February 25, 2026
{{cite web |title=Adma Biologics — Key figures — 10-K (0001140361-26-006815) |url=https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/ef20059416_10-k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.